Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepofarsen (QR-110) in Leber's Congenital Amaurosis 10 (LCA10)
NCT03913143Phase 3Active, not recruiting
- Sponsor
- ProQR Therapeutics
- Start
- Apr 2019
- Primary completion
- Jan 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of sepofarsen in Leber congenital amaurosis (LCA) (3 arms), sponsored by ProQR Therapeutics. Primary endpoint: Change in Best Corrected Visual Acuity at 12 months. Started Apr 2019; status: active, not recruiting.
02
Drugs
sepofarsen
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT03913143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913143.